Last checked at 31 Mar 2016 07:00
ValiRx Plc
("ValiRx" or "the Company")
ValiRx is exhibiting and presenting at the prestigious AACR
London, UK, 31st March 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, will be presenting its collaborative research at the American Association for Cancer Research Annual Conference in New Orleans starting on April 16th 2016. The Conference is an annual event designed to showcase and bring together developments in all major areas of cancer research. There were nearly 20,000 participants in attendance last year.
ValiRx therapeutics and diagnostics are further exhibiting and promoting its products, therapeutics and services to the wider participating oncology community, including the individual researcher up to multinational research and pharmaceutical organisations, many of whom are attending the conference. The profile of the exhibition and the promotion of the presentations will be supported by Burns McClellan, the leading US-based consultancy, who will assist in making wider connections while the Company concentrates on strengthening its current relationships. Valirx will also be using the opportunity to promote the excellent results being seen in the clinical trial for VAL201.
Satu Vainikka, Chief Executive of ValiRx, commented: "This is another great opportunity for us to show the excellence of our technology and products in a large international arena."
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 mark.treharne@valirx.com |
Northland Capital Partners Limited (Broker) | Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) | |
About ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the AIM Market of the London Stock Exchange in October 2006.
The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company. The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.
2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.